Latest Press Releases

San Francisco, Calif., May 20, 2008 /PRNewswire/ -- ASINEX and Collaborative Drug Discovery (CDD), Inc have formed a collaboration showcasing ASINEX high value compound libraries via the CDD Community Database.

L'Aquila, Moscow May 28th 2007:DOMPE' and ASINEX are pleased to announce a successful project which involved the rapid synthesis and purification of a large targeted orientated library of small molecules using High Throughput Chemistry (HTC) methodology.

MOSCOW, RUSSIA - May, 2006 - ASINEX Ltd, a worldwide leader in lead generation and lead optimization, announced today that Johnson & Johnson Pharmaceutical Research & Development, (J&JPRD), Division of Janssen Pharmaceutica N.V., has renewed its discovery chemistry collaboration with ASINEX. ASINEX has provided a range of chemistry services to J&JPRD since 2002 that includes the synthesis of exclusive libraries, lead optimization and custom synthesis.

Munich, Germany and Moscow, Russia, June 6, 2006 - Ingenium Pharmaceuticals AG, a drug discovery and development company, and ASINEX Ltd., a leading provider of lead generation and chemical optimization services, announced today a successful lead optimization project resulting in the generation of novel active compounds, which will expand Ingenium's current proprietary pipeline of potential treatments for pain and inflammatory diseases. Due to the success of this completed project, the two companies will continue the collaboration throughout 2006.

Moscow, January, 2006-ASINEX, a leading provider of Lead Generation and Optimization services, today announced the successful completion of 3 years of discovery chemistry services for Basilea Pharmaceutica Ltd (Switzerland), a biopharmaceutical company focusing on discovery and development of novel drugs for high unmet medical needs in the fields of anti-bacterials, anti-fungals and dermatology. The deal was initially signed in 2002.

Moscow, Russia, 11th of July 2005 - ASINEX Ltd, a worldwide leader in lead generation and lead optimization announces the triggering of its first milestone payment as a part of a drug discovery collaboration with Biovitrum AB, a European Biotech company focusing on metabolic diseases R&D. ASINEX has achieved screening results which have met the set criteria of Biovitrum for an undisclosed GPCR target.

Moscow, 21st of November 2005 - ASINEX Ltd, a worldwide leader in lead generation and lead optimization, and Merz Pharmaceuticals GmbH, announce the prolongation of an integrated drug discovery project focused on a CNS target.